Special 5/2013

  • Biocapital

    In this issue:

    Good biocapital access – for a few

    In an era when payers are increasingly also looking at the economic benefits a new therapeutic has to offer, biotechs have to prove not only safety and efficacy to regulators, but cost-effectiveness to reimbursers as well. Both factors are subject to due dilligence when it comes time to apply for financing. That's why convincing investors of the value of product portfolios – which are most often developed by biotech innovators – has become a complex task. Market forecasts by Prime Therapeutics/Blue Cross-Blue Shield predict specialty drugs will account for 50% of all drug costs by 2018 (up from 20% in 2009). But the most current Global Biotech Report released by Ernst & Young at the end of April says despite that promising future, just a few large biotechs are benefiting from financing.

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM



Alle Kurse


  • MOLOGEN7.80 EUR4.00%
  • MAGFORCE6.45 EUR3.20%
  • CO.DON2.50 EUR2.88%


  • WILEX2.10 EUR-7.08%
  • CYTOS0.26 CHF-3.70%
  • ADDEX4.03 CHF-1.71%


  • WILEX2.10 EUR162.5%
  • MAGFORCE6.45 EUR16.2%
  • BB BIOTECH136.80 EUR6.5%


  • VITA 343.89 EUR-22.4%
  • MOLOGEN7.80 EUR-19.3%
  • PAION2.42 EUR-16.6%


  • SANTHERA67.95 CHF3247.3%
  • PAION2.42 EUR231.5%
  • CO.DON2.50 EUR212.5%


  • CYTOS0.26 CHF-93.6%
  • MEDIGENE4.65 EUR-67.2%
  • THERAMETRICS0.08 CHF-50.0%

No liability assumed, Date: 18.08.2014